Merikangas KR et al (1998) Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 23(6):893–907

Article  CAS  PubMed  Google Scholar 

Peacock A et al (2018) Global statistics on alcohol, Tobacco and illicit drug use: 2017 status report. Addiction 113(10):1905–1926

Article  PubMed  Google Scholar 

Azevedo CA, Mammis A (2018) Neuromodulation therapies for Alcohol Addiction: A literature review. Neuromodulation 21(2):144–148

Article  PubMed  Google Scholar 

Gajbhiye SV et al (2018) Minocycline in Alcohol Withdrawal Induced anxiety and alcohol relapse in rats. Curr Clin Pharmacol 13(1):65–72

Article  CAS  PubMed  Google Scholar 

Ribadier A, Varescon I (2019) Anxiety and depression in Alcohol Use Disorder individuals: the role of personality and coping strategies. Subst Use Misuse 54(9):1475–1484

Article  PubMed  Google Scholar 

Conway KP et al (2016) Association of Lifetime Mental Disorders and subsequent alcohol and Illicit Drug Use: results from the National Comorbidity Survey-Adolescent supplement. J Am Acad Child Adolesc Psychiatry 55(4):280–288

Article  PubMed  Google Scholar 

Peris J et al (2022) Conditioned social preference and reward value of activating oxytocin-receptor-expressing ventral tegmental area neurons following repeated daily binge ethanol intake. Alcohol Clin Exp Res 46(2):194–206

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho AL et al (2018) The nucleus accumbens and Alcoholism: a target for deep brain stimulation. Neurosurg Focus 45(2):E12

Article  PubMed  Google Scholar 

Shang P et al (2020) Chronic Alcohol exposure induces aberrant mitochondrial morphology and inhibits respiratory capacity in the Medial Prefrontal cortex of mice. Front Neurosci 14:561173

Article  PubMed  PubMed Central  Google Scholar 

King JA et al (2020) Chronic alcohol-induced liver injury correlates with memory deficits: role for neuroinflammation. Alcohol 83:75–81

Article  CAS  PubMed  Google Scholar 

Russo SJ, Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci 14(9):609–625

Article  CAS  PubMed  Google Scholar 

Lodge DJ, Grace AA (2006) The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proc Natl Acad Sci U S A 103(13):5167–5172

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Sirohi S et al (2016) Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav 161:140–144

Article  CAS  PubMed  Google Scholar 

Jerlhag E (2018) GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology 136(Pt B):343–349

Article  CAS  PubMed  Google Scholar 

Marty VN et al (2020) Long-Acting Glucagon-Like Peptide-1 receptor agonists suppress Voluntary Alcohol Intake in male Wistar rats. Front Neurosci 14:599646

Article  PubMed  PubMed Central  Google Scholar 

Graham DL et al (2020) A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain. J Comp Neurol 528(14):2445–2470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reich N, Hölscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s Disease: an in-depth review. Front Neurosci 16:970925

Article  PubMed  PubMed Central  Google Scholar 

Suchankova P et al (2015) The glucagon-like peptide-1 receptor as a potential treatment target in Alcohol Use Disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry 5(6):e583

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sørensen G, Caine SB, Thomsen M (2016) Effects of the GLP-1 agonist Exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin Exp Res 40(10):2247–2252

Article  PubMed  PubMed Central  Google Scholar 

Shirazi RH, Dickson SL, Skibicka KP (2013) Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS ONE 8(4):e61965

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Vallof D, Kalafateli AL, Jerlhag E (2019) Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Psychoneuroendocrinology 103:284–295

Article  PubMed  Google Scholar 

Colvin KJ et al (2020) Brain site-specific inhibitory effects of the GLP-1 Analogue Exendin-4 on alcohol intake and operant responding for palatable food. Int J Mol Sci 21(24):9710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomsen M et al (2017) The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol Biochem Behav 160:14–20

Article  CAS  PubMed  Google Scholar 

Klausen MK et al (2022) Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 7(19):e159863

Article  PubMed  PubMed Central  Google Scholar 

Vilsboll T (2009) Liraglutide: a new treatment for type 2 Diabetes. Drugs Today (Barc) 45(2):101–113

Article  PubMed  Google Scholar 

McClean P et al (2011) The Diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer’s Disease. J Neurosci 31:6587–6594

Article  CAS  PubMed  PubMed Central  Google Scholar 

McClean PL, Holscher C (2014) Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology 76:57–67

Article  CAS  PubMed  Google Scholar 

Parthsarathy V, Holscher C (2013) The type 2 Diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol 700(1–3):42–50

Article  CAS  PubMed  Google Scholar 

Hölscher C (2022) Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol 179(4):695–714

Article  PubMed  Google Scholar 

Femminella GD et al (2019) Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s Disease: study protocol for a randomised controlled trial (ELAD study). Trials 20(1):191

Article  PubMed  PubMed Central  Google Scholar 

Edison P et al (2023) MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE. Alzheimer’s  Dementia 19:e080538

Article  Google Scholar 

Hogg E et al (2023) A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson’s Disease. Available at SSRN. https://ssrn.com/abstract=4212371

Mansur RB et al (2017) Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 207:114–120

Article  CAS  PubMed  Google Scholar 

Mansur RB et al (2017) Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. Eur Neuropsychopharmacol 27(11):1153–1162

Article  CAS  PubMed  Google Scholar 

Chuong V et al (2023) The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8(12):e170671

Sharma M, Jalewa J, Holscher C (2013) Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 128:459–471

Article  PubMed  Google Scholar 

Simms JA et al (2008) Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res 32(10):1816–1823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Egecioglu E et al (2013) The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38(8):1259–1270

Article  CAS  PubMed  Google Scholar 

Hunter K, Holscher C (2012) Drugs developed to treat Diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13(1):33–38

Article  CAS  PubMed